Hypersensitivity Reactions: Exaggerated Immune Responses
Hypersensitivity reactions occur when the immune system mounts an excessive, inappropriate, or misdirected response to a stimulus that would otherwise be harmless. Rather than protecting the host, the immune response itself becomes the cause of tissue injury. These reactions range from immediate, life-threatening responses to delayed, chronic inflammatory processes. Hypersensitivity reflects immune dysregulation rather than immune strength.
What You Need to Know
Hypersensitivity reactions occur when immune responses are exaggerated, inappropriate, or misdirected toward antigens that pose little or no actual threat. The immune system identifies an antigen and mounts a response that is disproportionate to the stimulus, leading to inflammation, tissue injury, and clinical symptoms. Importantly, the damage seen in hypersensitivity reactions is caused by immune mechanisms themselves rather than direct toxicity or invasiveness of the antigen. This means the host response, not the trigger, is responsible for pathology.
Once a hypersensitivity response is established, immune activation tends to recur with repeated exposure to the same antigen. Prior sensitisation lowers the threshold for future responses, so subsequent encounters can produce faster and more intense reactions. The clinical impact depends on the immune pathways involved, the tissue targeted, and the speed of the response rather than the amount of antigen present.
Several core principles explain how hypersensitivity reactions cause disease:
immune responses are disproportionate to the actual threat posed by the antigen
tissue damage results from immune mediators such as antibodies, cytokines, or immune cells
prior sensitisation shapes the intensity and timing of future reactions
Hypersensitivity reactions are grouped into four types based on the dominant immune mechanism responsible for injury. These categories describe how tissue damage occurs, not the severity of the reaction. Different immune cells, antibodies, and inflammatory mediators dominate each type, and different tissues are affected as a result. Understanding the underlying mechanism clarifies why reactions present differently, why some are immediate while others are delayed, and why management strategies vary depending on the immune pathway involved rather than the trigger alone.
Beyond the Basics
Type I hypersensitivity: immediate IgE-mediated reactions
Type I hypersensitivity is driven by IgE antibodies bound to mast cells and basophils. During initial exposure, sensitisation occurs as antigen-specific IgE is produced and attaches to Fc receptors on mast cells. On re-exposure, the antigen cross-links surface-bound IgE, triggering rapid mast cell degranulation and release of pre-formed mediators such as histamine, along with newly synthesised leukotrienes and prostaglandins.
The clinical effects occur within minutes because mediators are released immediately rather than requiring new immune synthesis. Vasodilation, increased vascular permeability, bronchoconstriction, and mucus secretion dominate the response. Severity depends on the extent of mediator release and the tissues involved, explaining why reactions range from local urticaria to life-threatening anaphylaxis. Repeated exposure increases risk because sensitisation lowers the activation threshold.
Type II hypersensitivity: antibody-mediated cytotoxicity
Type II hypersensitivity occurs when IgG or IgM antibodies bind directly to antigens on the surface of host cells or extracellular matrix components. Antibody binding activates complement or recruits immune effector cells, leading to targeted destruction of the antigen-bearing cells. The immune system misidentifies normal tissue as foreign.
Cell injury occurs through complement-mediated lysis or antibody-dependent cellular cytotoxicity. Damage is confined to tissues expressing the target antigen, so clinical manifestations depend on the affected cell type. This mechanism explains disorders involving haemolysis, platelet destruction, or tissue-specific injury rather than systemic inflammatory responses.
Type III hypersensitivity: immune complex-mediated injury
Type III hypersensitivity results from formation of circulating antigen–antibody complexes that are not efficiently cleared. These complexes deposit in tissues, particularly where filtration pressure is high, such as small blood vessels, kidneys, joints, and skin. Once deposited, they activate complement and attract neutrophils. Inflammation develops at the site of deposition rather than where the antigen was introduced. Tissue damage arises from release of proteolytic enzymes and reactive oxygen species by recruited inflammatory cells. Because immune complex formation and deposition take time, symptoms are delayed and may be systemic, explaining fever, rash, arthritis, or renal involvement appearing days after exposure.
Type IV hypersensitivity: delayed T-cell-mediated reactions
Type IV hypersensitivity is mediated by sensitised T lymphocytes rather than antibodies. Upon re-exposure, antigen-specific T cells release cytokines that recruit and activate macrophages and other inflammatory cells. Tissue injury results from sustained cellular inflammation rather than rapid mediator release. Reactions typically develop 24–72 hours after exposure, reflecting the time required for T-cell activation and cell recruitment. Because antibodies are not involved, these responses are slower and often more localised. This mechanism underlies contact dermatitis, granulomatous inflammation, and other delayed immune-mediated conditions.
Why hypersensitivity causes tissue damage
Across all hypersensitivity types, tissue injury arises from immune effector mechanisms rather than direct antigen toxicity. Mediator release, vascular leakage, immune cell recruitment, and targeted cellular destruction disrupt normal tissue structure and function. When exposure is repeated or ongoing, inflammation becomes chronic.
Chronic or recurrent hypersensitivity responses lead to cumulative tissue injury, fibrosis, and functional impairment. This explains why avoidance of triggers and modulation of immune pathways are central to management, as continued immune activation progressively worsens tissue damage even when individual reactions appear self-limited.
Clinical Connections
Hypersensitivity reactions present with wide clinical variation because symptoms are determined by immune mechanism, timing, and tissue involvement rather than by antigen dose or toxicity. Reactions may be immediate or delayed, confined to a single tissue or systemic, and mild or rapidly life-threatening. Early features are often non-specific, and severity at presentation does not reliably predict progression. Accurate recognition depends on linking symptom onset to exposure history and understanding how different immune pathways generate distinct clinical patterns.
Several recurring features help differentiate hypersensitivity mechanisms in practice:
rapid onset of symptoms minutes after exposure, suggesting IgE-mediated mast cell activation
delayed inflammation hours to days after exposure, consistent with T-cell–mediated responses
tissue-specific injury such as haemolysis, nephritis, or vasculitis indicating antibody or immune complex involvement
Clinical risk lies in progression rather than initial appearance. Immediate hypersensitivity can escalate quickly due to widespread mediator release and vascular effects, while delayed reactions may evolve insidiously with accumulating tissue injury. Monitoring focuses on trend and trajectory, including spread of symptoms, involvement of additional organ systems, and response to early intervention. Escalation is guided by physiological change and pattern recognition rather than symptom intensity alone, particularly in systemic reactions where early deterioration may be subtle but rapid once established.
Concept Check
Why are hypersensitivity reactions considered immune-mediated tissue injury?
What distinguishes immediate from delayed hypersensitivity reactions?
How do immune complexes cause tissue damage in Type III hypersensitivity?
Why does Type IV hypersensitivity take longer to develop?
Why can repeated exposure worsen hypersensitivity reactions?